- Home
- ALXO vs XTNT Comparison
ALXO vs XTNT Comparison
Compare ALXO & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- XTNT
- Stock Information
- Founded
- ALXO 2015
- XTNT N/A
- Country
- ALXO United States
- XTNT United States
- Employees
- ALXO N/A
- XTNT N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALXO Health Care
- XTNT Health Care
- Exchange
- ALXO Nasdaq
- XTNT Nasdaq
- Market Cap
- ALXO 93.7M
- XTNT 112.1M
- IPO Year
- ALXO 2020
- XTNT N/A
- Fundamental
- Price
- ALXO $1.26
- XTNT $0.80
- Analyst Decision
- ALXO Strong Buy
- XTNT
- Analyst Count
- ALXO 6
- XTNT 0
- Target Price
- ALXO $3.30
- XTNT N/A
- AVG Volume (30 Days)
- ALXO 424.8K
- XTNT 404.4K
- Earning Date
- ALXO 11-07-2025
- XTNT 11-11-2025
- Dividend Yield
- ALXO N/A
- XTNT N/A
- EPS Growth
- ALXO N/A
- XTNT N/A
- EPS
- ALXO N/A
- XTNT N/A
- Revenue
- ALXO N/A
- XTNT $127,766,000.00
- Revenue This Year
- ALXO N/A
- XTNT $13.03
- Revenue Next Year
- ALXO N/A
- XTNT N/A
- P/E Ratio
- ALXO N/A
- XTNT N/A
- Revenue Growth
- ALXO N/A
- XTNT 15.16
- 52 Week Low
- ALXO $0.40
- XTNT $0.33
- 52 Week High
- ALXO $2.27
- XTNT $0.95
- Technical
- Relative Strength Index (RSI)
- ALXO 38.76
- XTNT 51.54
- Support Level
- ALXO $1.49
- XTNT $0.75
- Resistance Level
- ALXO $1.64
- XTNT $0.95
- Average True Range (ATR)
- ALXO 0.14
- XTNT 0.08
- MACD
- ALXO -0.05
- XTNT -0.01
- Stochastic Oscillator
- ALXO 4.13
- XTNT 38.68
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.